• / Free eNewsletters & Magazine
  • / My Account
Home>Stocks>Alnylam Pharmaceuticals

Alnylam Pharmaceuticals

  1. All
  2. 3rd Party
  1. Global Hepatocellular Carcinoma (Nexavar & Miripla) Drug Sales 2017 - Pipeline Analysis and Market Forecast 2022 - Research and Markets

    Global Hepatocellular Carcinoma (Nexavar & Miripla) Drug Sales 2017 - Pipeline Analysis and Market Forecast 2022 - Research and Markets

  2. Dodge & Cox Balanced Fund Isn't for Everyone

    This Gold-rated fund is not a safe choice, but it's a strong one for the right kind of investor.

  3. Investing in Hidden Assets

    Use this screen to find high-growth businesses that have big ideas to keep competitors at bay.

©2017 Morningstar Advisor. All right reserved.